Senior Manager – Rare Endo & Rare Tumors Marketing Operations Lead
Alexion
Senior Manager – Rare Endo & Rare Tumors Marketing Operations Lead
Alexion
Global biopharmaceuticals focusing on rare diseases
This is what you will do:
The Senior Manager, Marketing Operations is responsible for leading operational planning, execution, and cross-functional coordination for the U.S. Rare Endocrinology and Rare Tumor business. Reporting to the Executive Director, U.S. Rare Endocrinology Marketing, this role serves as a key operational partner to the marketing and field organizations, overseeing marketing operations processes, field resource deployment, print fulfillment and inventory management, vendor and agency management, Veeva CRM/Vault administration, national congress and meeting logistics, and launch readiness activities. The position also leads SOW/PO and budget operations as well as Quarterly and Annual Business Planning support to ensure seamless execution of strategic initiatives.
You will be responsible for:
You will need to have:
We would prefer for you to have:
The annual base pay (or hourly rate of compensation) for this position ranges from $115,795 to $173,693. Our positions offer eligibility for various incentives—an opportunity to receive short-term incentive bonuses, equity-based awards for salaried roles and commissions for sales roles. Benefits offered include qualified retirement programs, paid time off (i.e., vacation, holiday, and leaves), as well as health, dental, and vision coverage in accordance with the terms of the applicable plans.
Date Posted
09-Nov-2026Closing Date
22-Nov-2026Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion